<DOC>
	<DOCNO>NCT01394939</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy JX-594 ( Pexa-Vec ) administer intravenously either alone combination Irinotecan colorectal carcinoma patient refractory intolerant standard therapy .</brief_summary>
	<brief_title>Recombinant Vaccinia Virus Administered Intravenously Patients With Metastatic , Refractory Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologicallyconfirmed , advance metastatic colorectal cancer fail treatment fluoropyrimidine ( fluoruracil capecitabine ) oxaliplatin base therapy contradiction treatment drug determine investigator Failed treatment irinotecan Kras mutant tumor Kras wildtype fail cetuximab ( Erbitux ) panitumumab ( Vectibix ) contradiction treatment Regorafenibnaïve ( receive regorafenib ) ECOG 0 , 1 2 Measurable tumor ( ≥1 cm long diameter ) Acceptable health status determine investigator blood work ( Chemistry , Complete Blood Count , Coagulation ) Intolerant Irinotecan ( assign combination arm : Cohort 3 , Cohort 4 Combination Expansion Arm ) Treatment ketoconazole , enzymeinducing anticonvulsant St. John 's Wort ( assign combination arm ) Significant immunodeficiency due underlie illness and/or medication History severe exfoliative skin condition require systemic therapy within past 2 year Clinically significant and/or rapidly accumulate ascites , pericardial and/or pleural effusion Active cardiovascular disease , include limited significant coronary artery disease ( e.g. , require angioplasty stenting ) congestive heart failure within precede 12 month Viable CNS malignancy associate clinical symptom Received anticancer therapy within 4 week prior first treatment ( 6 week mitomycin c nitrosoureas ) Prior participation research protocol involve investigational medicinal product within 4 week prior first treatment Use prohibit antiviral medication , interferon/pegylated interferon ( PEGIFN ) ribavirin discontinue within 14 day prior JX 594 dose Inability suspend treatment antihypertensive medication 48 hour prior 48 hour JX594 treatment . Pregnant nursing infant Diagnosis chronic inflammatory bowel disease and/or bowel obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Vaccinia</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>JX-594</keyword>
	<keyword>Jennerex</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>oncolytic virus</keyword>
	<keyword>viral therapy</keyword>
	<keyword>RAS mutant</keyword>
	<keyword>Erbitux failure</keyword>
	<keyword>Oxaliplatin failure</keyword>
	<keyword>FOLFOX failure</keyword>
	<keyword>FOLFIRI failure</keyword>
	<keyword>Irinotecan failure</keyword>
	<keyword>Pexa-Vec</keyword>
</DOC>